PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 214 filers reported holding PDL BIOPHARMA INC in Q1 2015. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $783,000 | -55.9% | 303,534 | -63.1% | 0.00% | -50.0% |
| Q1 2017 | $1,776,000 | +536.6% | 822,592 | +525.9% | 0.00% | +100.0% |
| Q4 2016 | $279,000 | -43.4% | 131,433 | -10.8% | 0.00% | 0.0% |
| Q3 2016 | $493,000 | -27.0% | 147,281 | -31.5% | 0.00% | 0.0% |
| Q2 2016 | $675,000 | -20.2% | 214,879 | -19.5% | 0.00% | -50.0% |
| Q1 2016 | $846,000 | -98.7% | 266,935 | -96.9% | 0.00% | -98.5% |
| Q4 2014 | $66,959,000 | -99.9% | 8,684,695 | -0.4% | 0.13% | +50.6% |
| Q3 2014 | $65,154,797,000 | -22.9% | 8,722,195 | -0.1% | 0.09% | -17.1% |
| Q2 2014 | $84,498,075,000 | +15.6% | 8,729,140 | -0.8% | 0.10% | +28.0% |
| Q1 2014 | $73,103,402,000 | +69.1% | 8,797,040 | +71.8% | 0.08% | +51.9% |
| Q4 2013 | $43,222,658,000 | +27.0% | 5,121,168 | +20.0% | 0.05% | -34.9% |
| Q3 2013 | $34,020,487,000 | +27.2% | 4,268,568 | +23.2% | 0.08% | +16.9% |
| Q2 2013 | $26,737,201,000 | – | 3,463,368 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nine Chapters Capital Management LLC | 119,700 | $254,000 | 0.43% |
| GSA CAPITAL PARTNERS LLP | 1,587,756 | $3,366,000 | 0.20% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 60,901 | $129,110,000 | 0.14% |
| Acrospire Investment Management LLC | 129,480 | $274,000 | 0.11% |
| SECOR Capital Advisors, LP | 410,323 | $870,000 | 0.11% |
| RBF Capital, LLC | 251,421 | $540,000 | 0.08% |
| Park West Asset Management LLC | 400,000 | $848,000 | 0.07% |
| MACKENZIE FINANCIAL CORP | 4,687,825 | $9,938,000 | 0.06% |
| CIGNA INVESTMENTS INC /NEW | 261,533 | $554,000,000 | 0.06% |
| ACADIAN ASSET MANAGEMENT LLC | 5,503,285 | $11,665,000 | 0.06% |